Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
270
USD
|
+0.22%
|
|
+0.39%
|
-6.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
143,240
|
133,852
|
126,718
|
140,139
|
154,142
|
144,811
|
-
|
-
|
Enterprise Value (EV)
1 |
164,232
|
156,191
|
151,990
|
169,779
|
207,811
|
191,281
|
185,093
|
180,338
|
P/E ratio
|
18.7
x
|
18.7
x
|
21.9
x
|
21.7
x
|
23.1
x
|
23.5
x
|
18.2
x
|
17.3
x
|
Yield
|
2.41%
|
2.78%
|
3.13%
|
2.95%
|
2.96%
|
3.43%
|
3.72%
|
3.95%
|
Capitalization / Revenue
|
6.13
x
|
5.26
x
|
4.88
x
|
5.32
x
|
5.47
x
|
4.39
x
|
4.24
x
|
4.13
x
|
EV / Revenue
|
7.03
x
|
6.14
x
|
5.85
x
|
6.45
x
|
7.37
x
|
5.8
x
|
5.42
x
|
5.14
x
|
EV / EBITDA
|
12.3
x
|
9.8
x
|
9.61
x
|
10.5
x
|
11.9
x
|
9.89
x
|
9.34
x
|
8.6
x
|
EV / FCF
|
19.2
x
|
15.8
x
|
18.1
x
|
19.3
x
|
28.2
x
|
13.6
x
|
15.1
x
|
14.3
x
|
FCF Yield
|
5.2%
|
6.33%
|
5.51%
|
5.17%
|
3.54%
|
7.38%
|
6.63%
|
6.99%
|
Price to Book
|
14.7
x
|
14.1
x
|
18.7
x
|
38.3
x
|
24.7
x
|
18.2
x
|
13.3
x
|
10.8
x
|
Nbr of stocks (in thousands)
|
594,184
|
582,169
|
563,266
|
533,579
|
535,178
|
536,376
|
-
|
-
|
Reference price
2 |
241.1
|
229.9
|
225.0
|
262.6
|
288.0
|
270.0
|
270.0
|
270.0
|
Announcement Date
|
1/30/20
|
2/2/21
|
2/7/22
|
1/31/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
23,362
|
25,424
|
25,979
|
26,323
|
28,190
|
32,951
|
34,144
|
35,084
|
EBITDA
1 |
13,363
|
15,935
|
15,822
|
16,178
|
17,470
|
19,332
|
19,817
|
20,962
|
EBIT
1 |
11,157
|
12,334
|
12,424
|
12,761
|
13,399
|
15,078
|
15,690
|
16,135
|
Operating Margin
|
47.76%
|
48.51%
|
47.82%
|
48.48%
|
47.53%
|
45.76%
|
45.95%
|
45.99%
|
Earnings before Tax (EBT)
1 |
9,138
|
8,133
|
6,701
|
7,346
|
7,855
|
6,554
|
8,985
|
8,801
|
Net income
1 |
7,842
|
7,264
|
5,893
|
6,552
|
6,717
|
6,121
|
7,560
|
8,119
|
Net margin
|
33.57%
|
28.57%
|
22.68%
|
24.89%
|
23.83%
|
18.57%
|
22.14%
|
23.14%
|
EPS
2 |
12.88
|
12.31
|
10.28
|
12.11
|
12.49
|
11.48
|
14.86
|
15.57
|
Free Cash Flow
1 |
8,532
|
9,889
|
8,381
|
8,785
|
7,359
|
14,115
|
12,277
|
12,600
|
FCF margin
|
36.52%
|
38.9%
|
32.26%
|
33.37%
|
26.11%
|
42.84%
|
35.96%
|
35.91%
|
FCF Conversion (EBITDA)
|
63.85%
|
62.06%
|
52.97%
|
54.3%
|
42.12%
|
73.01%
|
61.95%
|
60.11%
|
FCF Conversion (Net income)
|
108.8%
|
136.14%
|
142.22%
|
134.08%
|
109.56%
|
230.61%
|
162.4%
|
155.18%
|
Dividend per Share
2 |
5.800
|
6.400
|
7.040
|
7.760
|
8.520
|
9.269
|
10.03
|
10.67
|
Announcement Date
|
1/30/20
|
2/2/21
|
2/7/22
|
1/31/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
6,706
|
6,846
|
6,238
|
6,594
|
6,652
|
6,839
|
6,105
|
6,986
|
6,903
|
8,196
|
7,457
|
8,311
|
8,422
|
8,801
|
7,911
|
EBITDA
1 |
4,302
|
3,849
|
3,981
|
4,163
|
4,114
|
3,920
|
3,721
|
4,411
|
4,298
|
5,040
|
4,437
|
5,116
|
5,250
|
5,339
|
-
|
EBIT
1 |
3,452
|
2,997
|
3,140
|
3,335
|
3,277
|
3,009
|
2,821
|
3,515
|
3,403
|
3,660
|
3,171
|
3,887
|
3,991
|
4,029
|
3,776
|
Operating Margin
|
51.48%
|
43.78%
|
50.34%
|
50.58%
|
49.26%
|
44%
|
46.21%
|
50.31%
|
49.3%
|
44.66%
|
42.53%
|
46.77%
|
47.39%
|
45.77%
|
47.73%
|
Earnings before Tax (EBT)
1 |
2,155
|
2,131
|
1,675
|
1,531
|
2,392
|
1,748
|
3,442
|
1,614
|
1,947
|
852
|
1,214
|
1,780
|
1,790
|
1,010
|
2,995
|
Net income
1 |
1,884
|
1,899
|
1,476
|
1,317
|
2,143
|
1,616
|
2,841
|
1,379
|
1,730
|
767
|
1,143
|
1,702
|
1,828
|
1,560
|
2,018
|
Net margin
|
28.09%
|
27.74%
|
23.66%
|
19.97%
|
32.22%
|
23.63%
|
46.54%
|
19.74%
|
25.06%
|
9.36%
|
15.33%
|
20.48%
|
21.7%
|
17.73%
|
25.51%
|
EPS
2 |
3.310
|
3.360
|
2.680
|
2.450
|
3.980
|
3.000
|
5.280
|
2.570
|
3.220
|
1.420
|
2.708
|
3.254
|
3.600
|
2.975
|
3.780
|
Dividend per Share
2 |
1.760
|
1.760
|
1.940
|
1.940
|
1.940
|
1.940
|
2.130
|
2.130
|
2.130
|
2.130
|
2.314
|
2.314
|
2.314
|
2.314
|
2.580
|
Announcement Date
|
11/2/21
|
2/7/22
|
4/27/22
|
8/4/22
|
11/3/22
|
1/31/23
|
4/27/23
|
8/3/23
|
10/31/23
|
2/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
20,992
|
22,339
|
25,272
|
29,640
|
53,669
|
46,471
|
40,283
|
35,527
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.571
x
|
1.402
x
|
1.597
x
|
1.832
x
|
3.072
x
|
2.404
x
|
2.033
x
|
1.695
x
|
Free Cash Flow
1 |
8,532
|
9,889
|
8,381
|
8,785
|
7,359
|
14,115
|
12,277
|
12,600
|
ROE (net income / shareholders' equity)
|
81.4%
|
103%
|
122%
|
185%
|
203%
|
155%
|
197%
|
380%
|
ROA (Net income/ Total Assets)
|
14.3%
|
16%
|
15.8%
|
15.2%
|
12.4%
|
9.33%
|
10.1%
|
10.8%
|
Assets
1 |
54,778
|
45,481
|
37,328
|
43,230
|
54,315
|
65,603
|
74,518
|
74,970
|
Book Value Per Share
2 |
16.40
|
16.30
|
12.00
|
6.860
|
11.60
|
14.80
|
20.30
|
25.00
|
Cash Flow per Share
2 |
15.00
|
17.80
|
16.20
|
18.00
|
15.70
|
21.00
|
22.40
|
26.10
|
Capex
1 |
618
|
608
|
880
|
936
|
1,112
|
1,066
|
1,018
|
960
|
Capex / Sales
|
2.65%
|
2.39%
|
3.39%
|
3.56%
|
3.94%
|
3.23%
|
2.98%
|
2.74%
|
Announcement Date
|
1/30/20
|
2/2/21
|
2/7/22
|
1/31/23
|
2/6/24
|
-
|
-
|
-
|
Average target price
300.3
USD Spread / Average Target +11.22% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.26% | 145B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -11.77% | 144B |
Other Pharmaceuticals
|